• New EVERIC® lyo & amber combines an amber FIOLAX® glass vial with the proven EVERIC® lyo inner coating for lyophilized, light-sensitive antibody-drug conjugates (ADCs)
• Provides dependable light protection directly at the primary container level—beginning during fill-and-finish
• EVERIC® amber is the first specialty vial designed for highly light-sensitive drugs to meet pharmacopoeial light-transmission requirements in the EU, U.S., and Japan

SCHOTT Pharma, a specialist in drug containment and delivery solutions, is expanding its EVERIC® portfolio with EVERIC® lyo & amber—an amber-colored vial made from FIOLAX® amber pharma glass and enhanced with the EVERIC® lyo hydrophobic inner coating. The new configuration is designed for lyophilized, highly light-sensitive biologics, with a particular focus on next-generation ADCs used in targeted oncology therapies.

“ADCs are advancing rapidly and place new demands on primary packaging,” says Andreas Reisse, CEO of SCHOTT Pharma. “With EVERIC® lyo & amber, we’re providing a solution that helps protect these sensitive medicines right from the start of manufacturing.”

Light protection where it starts: the primary container

As more therapies show light sensitivity early in production, protection via secondary packaging alone can be insufficient. EVERIC® lyo & amber addresses this by delivering controlled, certified light protection directly through the vial, including during filling and processing. With tightly managed light transmission performance, the new amber vial is positioned as the first specialty vial to align with light-transmission requirements across Europe, the United States, and Japan.

SCHOTT Pharma will present the new vial at Pharmapack Paris (January 21–22), Hall 4, Booth G38.

Supporting one of oncology’s most complex drug types

ADCs combine an antibody with a highly potent payload, enabling targeted treatment while aiming to reduce systemic toxicity. However, these products can be highly sensitive and costly, and light exposure may impact stability, efficacy, and shelf life. For ADCs with high photosensitivity, consistent light protection throughout manufacturing, storage, and use is essential—starting at fill-and-finish.

Built for lyophilized ADCs

EVERIC® lyo & amber pairs FIOLAX® amber borosilicate glass with SCHOTT Pharma’s EVERIC® lyo coating. The vials are produced using a precisely controlled hot-forming process, enabling tight dimensional tolerances and defined light transmission characteristics suited to light-sensitive medicines.

For lyophilized products, the hydrophobic EVERIC® lyo inner surface is designed to support manufacturing efficiency and product performance by:

• helping reduce fogging during lyophilization,
• improving residual emptying, and
• lowering the risk of product loss in high-value formulations.

The coating is applied using SCHOTT Pharma’s patented PICVD technology, creating a covalent bond with the glass surface. This approach differs from siliconization and is intended to avoid risks associated with free silicone in the drug product.

To support consistent performance and compliance, EVERIC® lyo & amber includes two in-production release criteria, documented in the Certificate of Analysis (CoA).

“With EVERIC® lyo & amber, we’re addressing the packaging needs of advanced ADCs—from the filling line through to administration,” says Diana Löber, Global Product Manager at SCHOTT Pharma.

Like other EVERIC® vials, EVERIC® lyo & amber is modular and customizable and is manufactured exclusively at SCHOTT Pharma’s site in Müllheim, Germany.